Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | EPRS1 | P07814 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6215307 | 0.85 | TDP1 (0.50) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL12756987 | 0.83 | TDP1 (0.49) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL1919502 | 0.81 | TDP1 (0.50) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL1262499 | 0.81 | L3MBTL1 (0.45) | ALDH1A1LMNAMAPK1HTT | |
| SCHEMBL20516073 | 0.80 | TDP1 (0.46) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL1505827 | 0.80 | TDP1 (0.61) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL4309406 | 0.79 | MAPT (0.62) | TDP1MAPTALDH1A1HSD17B10LMNA | |
| SCHEMBL6474772 | 0.79 | TDP1 (0.58) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL606872 | 0.79 | TDP1 (0.49) | TDP1MAPTALDH1A1HSD17B10POLB | |
| SCHEMBL14472134 | 0.78 | CYP1A2 (0.44) | ALDH1A1HSD17B10KDM4EHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024062090-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | WO | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-10072007-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| CN-103096893-A | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RES INC | 2013-05-08 | — | — | CN | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2427425-A2 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129057-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | TDP1 1640/4885MAPT 103/4885ALDH1A1 2605/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | TDP1 1640/4885MAPT 103/4885ALDH1A1 2605/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | TDP1 1640/4885MAPT 103/4885ALDH1A1 2605/4885 |
| US-10072007-B2 | Tetracycline compounds | TUBB, TUBA1C, TUBA1A | TDP1 1640/4885MAPT 103/4885ALDH1A1 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.